Xiaolu Pan1,2, Leonne Philippen1,2, Satadru K Lahiri1,2, Ciaran Lee3, So Hyun Park3, Tarah A Word1,2, Na Li1,2,4, Kelsey E Jarrett2, Rajat Gupta2, Julia O Reynolds1,2, Jean Lin1, Gang Bao3, William R Lagor2, Xander H T Wehrens1,2,4,5,6. 1. From the Cardiovascular Research Institute (X.P., L.P., S.K.L., T.A.W., N.L., J.O.R., J.L., X.H.T.W.), Baylor College of Medicine, Houston, TX. 2. Department of Molecular Physiology and Biophysics (X.P., L.P., S.K.L., T.A.W., N.L., K.E.J., R.G., J.O.R., W.R.L., X.H.T.W.), Baylor College of Medicine, Houston, TX. 3. Department of Bioengineering, Rice University, Houston, TX (C.L., S.H.P., G.B.). 4. Department of Medicine/Cardiology (N.L., X.H.T.W.), Baylor College of Medicine, Houston, TX. 5. Department of Pediatrics (X.H.T.W.), Baylor College of Medicine, Houston, TX. 6. Center for Space Medicine (X.H.T.W.), Baylor College of Medicine, Houston, TX.
Abstract
RATIONALE: Autosomal-dominant mutations in ryanodine receptor type 2 ( RYR2) are responsible for ≈60% of all catecholaminergic polymorphic ventricular tachycardia. Dysfunctional RyR2 subunits trigger inappropriate calcium leak from the tetrameric channel resulting in potentially lethal ventricular tachycardia. In vivo CRISPR/Cas9-mediated gene editing is a promising strategy that could be used to eliminate the disease-causing Ryr2 allele and hence rescue catecholaminergic polymorphic ventricular tachycardia. OBJECTIVE: To determine if somatic in vivo genome editing using the CRISPR/Cas9 system delivered by adeno-associated viral (AAV) vectors could correct catecholaminergic polymorphic ventricular tachycardia arrhythmias in mice heterozygous for RyR2 mutation R176Q (R176Q/+). METHODS AND RESULTS: Guide RNAs were designed to specifically disrupt the R176Q allele in the R176Q/+ mice using the SaCas9 ( Staphylococcus aureus Cas9) genome editing system. AAV serotype 9 was used to deliver Cas9 and guide RNA to neonatal mice by single subcutaneous injection at postnatal day 10. Strikingly, none of the R176Q/+ mice treated with AAV-CRISPR developed arrhythmias, compared with 71% of R176Q/+ mice receiving control AAV serotype 9. Total Ryr2 mRNA and protein levels were significantly reduced in R176Q/+ mice, but not in wild-type littermates. Targeted deep sequencing confirmed successful and highly specific editing of the disease-causing R176Q allele. No detectable off-target mutagenesis was observed in the wild-type Ryr2 allele or the predicted putative off-target site, confirming high specificity for SaCas9 in vivo. In addition, confocal imaging revealed that gene editing normalized the enhanced Ca2+ spark frequency observed in untreated R176Q/+ mice without affecting systolic Ca2+ transients. CONCLUSIONS: AAV serotype 9-based delivery of the SaCas9 system can efficiently disrupt a disease-causing allele in cardiomyocytes in vivo. This work highlights the potential of somatic genome editing approaches for the treatment of lethal autosomal-dominant inherited cardiac disorders, such as catecholaminergic polymorphic ventricular tachycardia.
RATIONALE: Autosomal-dominant mutations in ryanodine receptor type 2 ( RYR2) are responsible for ≈60% of all catecholaminergic polymorphic ventricular tachycardia. Dysfunctional RyR2 subunits trigger inappropriate calcium leak from the tetrameric channel resulting in potentially lethal ventricular tachycardia. In vivo CRISPR/Cas9-mediated gene editing is a promising strategy that could be used to eliminate the disease-causing Ryr2 allele and hence rescue catecholaminergic polymorphic ventricular tachycardia. OBJECTIVE: To determine if somatic in vivo genome editing using the CRISPR/Cas9 system delivered by adeno-associated viral (AAV) vectors could correct catecholaminergic polymorphic ventricular tachycardia arrhythmias in mice heterozygous for RyR2 mutation R176Q (R176Q/+). METHODS AND RESULTS: Guide RNAs were designed to specifically disrupt the R176Q allele in the R176Q/+ mice using the SaCas9 ( Staphylococcus aureus Cas9) genome editing system. AAV serotype 9 was used to deliver Cas9 and guide RNA to neonatal mice by single subcutaneous injection at postnatal day 10. Strikingly, none of the R176Q/+ mice treated with AAV-CRISPR developed arrhythmias, compared with 71% of R176Q/+ mice receiving control AAV serotype 9. Total Ryr2 mRNA and protein levels were significantly reduced in R176Q/+ mice, but not in wild-type littermates. Targeted deep sequencing confirmed successful and highly specific editing of the disease-causing R176Q allele. No detectable off-target mutagenesis was observed in the wild-type Ryr2 allele or the predicted putative off-target site, confirming high specificity for SaCas9 in vivo. In addition, confocal imaging revealed that gene editing normalized the enhanced Ca2+ spark frequency observed in untreated R176Q/+ mice without affecting systolic Ca2+ transients. CONCLUSIONS:AAV serotype 9-based delivery of the SaCas9 system can efficiently disrupt a disease-causing allele in cardiomyocytes in vivo. This work highlights the potential of somatic genome editing approaches for the treatment of lethal autosomal-dominant inherited cardiac disorders, such as catecholaminergic polymorphic ventricular tachycardia.
Authors: Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach Journal: Science Date: 2015-12-31 Impact factor: 47.728
Authors: Na Li; Tiannan Wang; Wei Wang; Michael J Cutler; Qiongling Wang; Niels Voigt; David S Rosenbaum; Dobromir Dobrev; Xander H T Wehrens Journal: Circ Res Date: 2011-12-08 Impact factor: 17.367
Authors: F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang Journal: Nat Protoc Date: 2013-10-24 Impact factor: 13.491
Authors: Nitin Mathur; Subeena Sood; Sufen Wang; Ralph J van Oort; Satyam Sarma; Na Li; Darlene G Skapura; J Henri Bayle; Miguel Valderrábano; Xander H T Wehrens Journal: Circ Arrhythm Electrophysiol Date: 2009-12
Authors: Mohit M Hulsurkar; Satadru K Lahiri; Jason Karch; Meng C Wang; Xander H T Wehrens Journal: Expert Opin Ther Targets Date: 2022-04-25 Impact factor: 6.797
Authors: Marco De Giorgi; Ang Li; Ayrea Hurley; Mercedes Barzi; Alexandria M Doerfler; Nikitha A Cherayil; Harrison E Smith; Jonathan D Brown; Charles Y Lin; Karl-Dimiter Bissig; Gang Bao; William R Lagor Journal: Mol Ther Methods Clin Dev Date: 2021-04-24 Impact factor: 6.698